Estrogen reduction by aromatase inhibition for benign prostatic hyperplasia: Results of a double-blind, placebo-controlled, randomized clinical trial using two doses of the aromatase-inhibitor atamestane

Prostate

Volumn 29, Issue 4, 1996, Pages 199-208

  Radlmaier, Albert ^a   Eickenberg, Hans U ^b   Fletcher, Matthew S ^c   Fourcade, Richard O ^d   Reis Santos, José M ^e   Van Aubel, Olav G J M ^f   Bono, Aldo V ^g  

^a BAYER PHARMA AG   (Germany)

^b FRANZISKUS HOSPITAL   (Germany)

^c BRIGHTON GENERAL HOSPITAL   (United Kingdom)

^d CENTRE HOSPITALIER   (France)

^e HOSPITAL CURRY CABRAL   (Portugal)

^f SINT FRANCISCUS GASTHUIS   (Netherlands)

^g Ospedale Multizonale Varese   (Italy)

Author keywords

aromatase inhibitor; BPH; estrogens

Indexed keywords

ATAMESTANE; FINASTERIDE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; ENZYME ACTIVITY; ENZYME INHIBITION; ESTRADIOL BLOOD LEVEL; ESTROGEN BLOOD LEVEL; ESTRONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MICTURITION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL;

AGED; ANDROGENS; ANDROSTENEDIONE; AROMATASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTRONE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; PROSTATIC HYPERPLASIA;

EID: 0029963510     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(199610)29:4<199::AID-PROS1>3.0.CO;2-7     Document Type: Article

References (31)

1. Berry SJ, Coffey DS, Walsh PC, Ewing LL: The development of human benign prostatic hyperplasia with age. J Urol 132:474-479, 1984.
2. Oesterling JE: The origin and development of benign prostatic hyperplasia - an age-dependent process. J Androl 12:348-355, 1991.
3. Guess HA, Arrighi HM, Metter EJ, Fozard JL: Cumulative prevalence of prostatism matches the autopsy prevalence of benign prostatic hyperplasia. Prostate 17: 241-246, 1990.
4. Garraway WM, Collins GN, Lee RJ: High prevalence of benign prostatic hypertrophy in the community. Lancet 338:469-471, 1991.
5. Chisholm GD: Benign prostatic hyperplasia: The best treatment. Br Med J 299:215-216, 1989.
6. Steg A, Ackermann R, Gibbons R, Jewett H, Koshiba K, Pearson B: Surgery in BPH. In Cockett ATK, Aso Y, Chatelain C, Denis L, Griffiths K, Khoury S, Murphy G (eds): "Proceedings: The International Consultation on Benign Prostatic Hyperplasia (BPH)." Jersey: Scientific Communication International Ltd., 1991, pp 203-221.
7. Dreikorn K, Richter R: Conservative nonhormonal treatment of patients with benign prostatic hyperplasia. In Ackermann R, Schröder FH (eds): "New Developments in Biosciences 5: Prostatic Hyperplasia." New York: Walter de Gruyter, 1989, pp 109-121.
8. Wu CP, Gu FL: The prostate in eunuchs. Progr Clin Biol Res 370:249-255, 1991.
9. Imperato-McGinley J, Gautier T, Zirinsky K, Hom T, Palomo O, Stein E, Darracott Vaughan E, Markisz JA, Ramirez de Arellano E, Kazam E: Prostate visualization studies in male homozygous and heterozygous for 5α-reductase deficiency. J Clin Endocrinol Metab 75:1022-1026, 1992.
10. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell J D, Andriole GL, Geller J, Bracken BR, Tenover JS, Darracott Vaughan E, Pappas F, Taylor A, Binkowitz B, Ng J, for the Finasteride Study Group: The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 327: 1185-1191, 1992.
11. The Finasteride Study Group: Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate 22:291-299, 1993.
12. Rittmaster RS: Drug therapy: finasteride. N Engl J Med 330:120-125, 1994.
13. Oesterling JE: Drug therapy: Benign prostatic hyperplasia: Medical and minimally invasive treatment options. N Engl J Med 332:99-109, 1995.
14. Rohr HP, Bartsch G: Stereological analysis: An approach to the pathogenesis of benign prostatic hyperplasia. In Hinman F. Jr (ed): "Benign Prostatic Hypertrophy." New York: Springer-Verlag, 1983, pp 112-129.
15. Seppelt U: Correlation among prostate stroma, plasma estrogen levels, and urinary estrogen excretion in patients with benign prostatic hypertrophy. J Clin Endocrinol Metab 47:1230-1235, 1978.
16. Pirke KM, Doerr P: Age related changes and interrelationships between plasma testosterone, estradiol and testosterone-binding globulin in normal adult males. Acta Endocrinol 74:792-800, 1973.
17. Habenicht UF, El Etreby FM: The periurethral zone of the prostate of the cynomolgus monkey is the most sensitive prostate part for an estrogenic stimulus. Prostate 13:305-316, 1988.
18. Habenicht UF, Schwarz K, Schweikert HU, Neumann F, El Etreby FM: Development of a model for the induction of estrogen-related prostatic hyperplasia in the dog and its response to the aromatase inhibitor 4-hydroxy-4-androstene-3, 17-dione: preliminary results. Prostate 8:181-194, 1986.
19. Henderson D, Norbisrath G, Kerb U: 1-Methyl-1,4-androstadiene-3,17-dione (SH 489): Characterization of an irreversible inhibitor of estrogen biosynthesis. J Steroid Biochem 24:303-306, 1986.
20. El Etreby FM, Nishino Y, Habenicht UF, Henderson D: Atamestane, a new aromatase inhibitor for the management of benign prostatic hyperplasia. J Androl 12:403-414, 1991.
21. Barry MJ, Fowler Jr. FJ, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, and the Measurement Committee of the American Urological Association: Correlation of the American Urological Association symptom index with self-administered versions of the Madsen-Iversen, Boyarsky and Maine medical assessment program symptom indexes. J Urol 148:1558-1563, 1992.
22. Boyarsky S, Jones G, Paulson DF, Prout GR Jr: A New look at bladder neck obstruction by the Food and Drug Administration Regulators: Guidelines for investigation of benign prostatic hypertrophy. Trans Am Assoc Gen Urin Surg 68:29-32, 1977.
23. Grino PB, Bruskewitz R, Blaivas JG, Siroky MB, Andersen JT, Cook T, Stoner E: Maximum urinary flow rate by uroflowmetry: Automatic or visual interpretation. J Urol 149:339-341, 1993.
24. Bolzmann A, Kreienberg R, Kaufmann M, Merkle E, (Atamestan-Studiengruppe): Phase-II-study of treatment of advanced breast cancer in postmenopausal women with the aromatase inhibitor atamestane. J Cancer Res Clin Oncol 118(Suppl):R123, 1992.
25. Coombes RC, Goss P, Dowsett M, Gazet JC, Brodie A: 4-Hydroxyandrostendione in treatment of postmenopausal patients with advanced breast cancer. Lancet 8414:1237-1239, 1989.
26. Höffken K, Jonat W, Possinger K, Kölbel M, Kunz T, Wagner H, Becher R, Callies R, Friedrich P, Willmanns W, Maass H, Schmidt CG: Aromatase inhibition with 4-hydroxyandrostendione in the treatment of post-menopausal patients with advanced breast cancer: A phase II study. J Clin Oncol 8:875-880, 1990.
27. Raats JI, Falkson G, Falkson HC: A study of fadrozole, a new aromatase inhibitor, in postmenopausal women with advanced metastatic breast cancer. J Clin Oncol 10:111-116, 1992.
28. Bhatnagar AS, Müller P, Schenkel L, Trunet PF, Beh I, Schieweck K: Inhibition of estrogen biosynthesis and its consequences on gonadotropin secretion in the male. J Steroid Biochem Mol Biol 41:437-443, 1992.
29. Trunet PF, Mueller P, Bhatnagar AS, Dickes I, Monnet G, White G: Open dose-finding study of a new potent and selective nonsteroidal aromatase inhibitor, CGS 20 267, in healthy male subjects. J Clin Endocrinol Metab 77:319-323, 1993.
30. Naftolin F, Ryan KJ, Davies IJ, Reddy VV, Flores F, Petro Z, Kuhn M, White RJ, Takaoka Y, Wolin L: The formation of estrogens by central neuroendocrine tissues. Recent Progr Horm Res 31:295, 1975.
31. Jardin A, Bensadoun H, Delauche-Cavallier MC, Attali P, BPH-ALF Group: Alfuzosin for treatment of benign prostatic hypertrophy. Lancet 337:1457-1461, 1991.